CEO John T. Treace purchased $59,213 worth of shares at $4.02, signaling confidence in the medical device maker. This purchase occurs as the stock has rallied 167% over the last 90 days, though it remains down nearly 50% from its 52-week high.
Price context
The stock is up 11.11% over the past five days and 54.15% over the last month, yet it remains down 33.56% from its 52-week low and 49.87% below the 52-week high of $7.78.
Catalysts to watch
- •Analysts have a wide range of price targets from US$2 to US$7 as of May 3, reflecting divergent views on product mix and launch timing.
- •Management reaffirmed its full-year 2026 revenue outlook on May 9, emphasizing new product adoption to drive procedure volume momentum.
- •The company reported a +9.68% earnings surprise and +2.75% revenue beat for Q1 2026 on May 8, setting the stage for the next earnings print.
Risks
- •The stock carries a high beta of 1.41, suggesting significant volatility relative to the broader market.
- •Short interest stands at 7.95% of the float, and analysts have a bearish bias with price targets as low as US$2.
AI-generated context from public data. Not investment advice. Verify before trading.